Subject: A survey among dermatologist to understand usage pattern of Amorolfine in dermatophytosis in India
Superficial fungal infections are caused by dermatophytes, non-dermatophytic moulds and commensal yeasts. Dermatophytes, the most common causative agents, are assuming high significance in developing countries like India. These organisms metabolize keratin and cause a range of pathologic clinical presentations, including tinea pedis, tinea corporis, tinea cruris, etc. The lesions may become widespread and may have significant negative social, psychological, and occupational health effects, and can compromise the quality of life significantly.
Currently, dermatologists across India are inundated with cases of dermatophytosis presenting with unusual large lesions, ring within ring lesions, multiple site lesions, and corticosteroid modified lesions, making diagnosis a difficult bet. This changed face of dermatophytosis has created a real panic among dermatologists. In addition, chronicity of the disease has plagued the patients unlike any other dermatological condition in the country.
Amorolfine, a morpholine derivative, is the first of a new class of antifungal drugs. The mechanism of action is inhibition of ergosterol biosynthesis in the fungal cell membrane. Alteration in the membrane sterol content leads to changes in membrane permeability and disruption of key fungal metabolic processes.
This dermatologist based survey has been undertaken to understand usage pattern of Amorolfine in dermatophytosis in India.
As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|